David Norman Cade
CIK: 0002123007
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
TLX
Telix Pharmaceuticals Ltd
Officer
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About Cade David Norman
Cade David Norman (SEC CIK 0002123007) files insider reports with the SEC as Group Chief Medical Officer of Telix Pharmaceuticals Ltd (TLX).
Signal8 holds 1 ownership filing by Cade David Norman, a Form 3, filed on Apr 1, 2026. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on Cade David Norman's filings is in NORTH MELBOURNE.
Other insiders filing for Telix Pharmaceuticals Ltd (TLX)
- Smith Darren Charlton, Group Chief Financial Officer
- GILL DAVID N, Director
- Jellison William R, Director
- Rivas Maria, Director
- Behrenbruch Christian, MD & Group CEO
- Nelson Mark Alexander, Director